Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program on June 14 in...
June 07 2016 - 8:10AM
- AM-101 has potential to be first-ever approved therapy for
tinnitus
- Top-line results from first of two Phase 3 trials expected in
August
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology, will host a breakfast meeting
focused on the treatment of acute inner ear tinnitus and AM-101's
Phase 3 clinical development program. The event will take place
from 8 am to 9:30 am EDT on Tuesday, June 14, 2016, in New York
City. The meeting will feature a presentation by Hinrich Staecker,
MD, PhD, who serves as a principal investigator in the Company's
TACTT2 trial, as well as presentations by members of the Auris
Medical leadership team.
This event will be held for investors and research
analysts. To reserve a seat, please contact Cindy McGee via e-mail
at investors@aurismedical.com. A live webcast will be available
through the Events and Presentations page in the Investors section
of the Auris Medical website at www.aurismedical.com, and a replay
of the presentation will be available following the event.
Hinrich Staecker, MD, PhD, completed medical school
at the Albert Einstein College of Medicine with distinction in
Otology Research. After completing his residency in otolaryngology
at Montefiore Medical Center, Dr. Staecker went on to a fellowship
in Otology and Neurotology at Harvard Medical School's
Massachusetts Eye and Ear. He is dual board certified in
Otolaryngology and Neurotology by the American Board of
Otolaryngology. Currently, Dr. Staecker is the David and Mary
Zamierowsky Professor at University of Kansas School of Medicine, a
member of the Collegium Oto-Rhino-Laryngologica, a fellow of the
Triological Society, and a member of the American Otological
Society.
The AM-101 Phase 3 clinical development program
includes the TACTT2 and TACTT3 trials. The TACTT2 trial has
enrolled more than 330 patients and is being conducted primarily in
North America under a Special Protocol Assessment (SPA) with the US
Food and Drug Administration. Top-line results from this trial are
expected in August 2016. The TACTT3 trial is being conducted in
Europe, and enrollment of approximately 630 patients (300 in the
acute stage and 330 in the post-acute stage) is expected to be
completed by the end of June 2016. Top-line results from this trial
are expected in the fourth quarter of 2016.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology. The Company is currently focusing
on the development of treatments for acute inner ear tinnitus
(AM-101) and for acute inner ear hearing loss (AM-111) by way of
intratympanic injection with biocompatible gel formulations. In
addition, Auris Medical is pursuing early-stage research and
development projects. The Company was founded in 2003 and is
headquartered in Zug, Switzerland. The shares of the parent company
Auris Medical Holding AG trade on the NASDAQ Global Market under
the symbol "EARS."
Forward-looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical fact and may include statements
that address future operating, financial or business performance or
Auris Medical's strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may,"
"might," "will," "should," "expects," "plans," "anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," and other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the timing and conduct of clinical trials of Auris
Medical's product candidates, the clinical utility of Auris
Medical's product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical's intellectual
property position and Auris Medical's financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Auris Medical's Annual Report
on Form 20-F and future filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date
they are made, and Auris Medical does not undertake any obligation
to update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
HUG#2018338
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Oct 2023 to Oct 2024